Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	neuropeptide Y receptor activity	QRFPR NPY4R2 NPY4R	2.67e-05	11	111	3	GO:0004983
GeneOntologyMolecularFunction	immunoglobulin receptor activity	CD200R1 FCGR3A FCGR3B	5.82e-05	14	111	3	GO:0019763
GeneOntologyMolecularFunction	glycosylated region protein binding	CD200R1 CLEC4G	9.15e-05	3	111	2	GO:0140081
GeneOntologyMolecularFunction	pancreatic polypeptide receptor activity	NPY4R2 NPY4R	1.82e-04	4	111	2	GO:0001602
GeneOntologyMolecularFunction	low-affinity IgG receptor activity	FCGR3A FCGR3B	1.82e-04	4	111	2	GO:0019772
GeneOntologyMolecularFunction	IgE receptor activity	FCGR3A FCGR3B	4.53e-04	6	111	2	GO:0019767
GeneOntologyMolecularFunction	IgE binding	FCGR3A FCGR3B	6.32e-04	7	111	2	GO:0019863
GeneOntologyMolecularFunction	IgG receptor activity	FCGR3A FCGR3B	6.32e-04	7	111	2	GO:0019770
GeneOntologyMolecularFunction	interleukin-17 receptor activity	IL17RE IL17RA	8.39e-04	8	111	2	GO:0030368
GeneOntologyMolecularFunction	transmembrane signaling receptor activity	PLXNA3 ERBB2 NTRK2 PTH2R CD200R1 MST1R QRFPR NPY4R2 P2RX5 NPY4R FCGR3A FCGR3B IL17RE UNC5C IL17RA FZD2 EDA2R	1.27e-03	1353	111	17	GO:0004888
GeneOntologyMolecularFunction	guanylate kinase activity	MAGI3 CARD11	1.63e-03	11	111	2	GO:0004385
GeneOntologyMolecularFunction	IgG binding	FCGR3A FCGR3B	1.63e-03	11	111	2	GO:0019864
GeneOntologyMolecularFunction	phosphatidylinositol binding	RAG2 BCAS3 ZCCHC2 PLA2G4E FCGR3A FCGR3B SNX18	1.94e-03	316	111	7	GO:0035091
GeneOntologyBiologicalProcess	perforin production	FCGR3A FCGR3B	2.72e-05	2	108	2	GO:0035944
GeneOntologyBiologicalProcess	negative regulation of T cell differentiation in thymus	RAG2 ERBB2 CLEC4G	3.84e-05	13	108	3	GO:0033085
GeneOntologyCellularComponent	Fc-gamma receptor III complex	FCGR3A FCGR3B	1.55e-04	4	107	2	GO:0033001
MousePheno	abnormal skin physiology	RAG2 RIPK4 PLA2G4E F5 GADD45A ABHD5 IL17RE CARD11 IL17RA WDR1 NIN	1.02e-06	288	83	11	MP:0005501
Domain	-	PLXNA3 SELENBP1 MED16 NBEAL1 BCAS3 MST1R CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	8.37e-10	333	108	15	2.130.10.10
Domain	WD40/YVTN_repeat-like_dom	PLXNA3 SELENBP1 MED16 NBEAL1 BCAS3 MST1R CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	9.09e-10	335	108	15	IPR015943
Domain	WD40	MED16 NBEAL1 BCAS3 CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	3.36e-08	259	108	12	PF00400
Domain	WD40	MED16 NBEAL1 BCAS3 CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	4.90e-08	268	108	12	SM00320
Domain	WD40_repeat	MED16 NBEAL1 BCAS3 CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	5.76e-08	272	108	12	IPR001680
Domain	WD_REPEATS_1	MED16 NBEAL1 BCAS3 CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	7.31e-08	278	108	12	PS00678
Domain	WD_REPEATS_2	MED16 NBEAL1 BCAS3 CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	7.60e-08	279	108	12	PS50082
Domain	WD_REPEATS_REGION	MED16 NBEAL1 BCAS3 CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	7.60e-08	279	108	12	PS50294
Domain	WD40_repeat_dom	MED16 NBEAL1 BCAS3 CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	1.50e-07	297	108	12	IPR017986
Domain	WD40_repeat_CS	CDC40 DCAF10 NLE1 CORO6 WDR1 CDC20 WDR17 FBXW7	4.98e-06	164	108	8	IPR019775
Domain	NPY_rcpt	QRFPR NPY4R2 NPY4R	1.54e-05	9	108	3	IPR000611
Domain	NPY4_rcpt	NPY4R2 NPY4R	3.31e-05	2	108	2	IPR001933
Domain	N2O_reductase_N	WDR1 CDC20 WDR17	8.13e-05	15	108	3	IPR011045
Domain	Apc4_WD40_dom	CORO6 CDC20 WDR17	2.00e-04	20	108	3	IPR024977
Domain	ANAPC4_WD40	CORO6 CDC20 WDR17	2.00e-04	20	108	3	PF12894
Domain	TSP_1	ADAMTSL1 PAPLN ISM2 UNC5C	4.84e-04	63	108	4	PF00090
Domain	SEFIR	IL17RE IL17RA	4.89e-04	6	108	2	PF08357
Domain	SEFIR_dom	IL17RE IL17RA	4.89e-04	6	108	2	IPR013568
Domain	SEFIR	IL17RE IL17RA	4.89e-04	6	108	2	PS51534
Domain	IPT	PLXNA3 PKHD1L1 MST1R	4.97e-04	27	108	3	SM00429
Domain	TSP1	ADAMTSL1 PAPLN ISM2 UNC5C	5.46e-04	65	108	4	SM00209
Domain	TSP1_rpt	ADAMTSL1 PAPLN ISM2 UNC5C	5.46e-04	65	108	4	IPR000884
Domain	TSP1	ADAMTSL1 PAPLN ISM2 UNC5C	5.46e-04	65	108	4	PS50092
Domain	TIG	PLXNA3 PKHD1L1 MST1R	7.51e-04	31	108	3	PF01833
Domain	Ig-like_fold	SLAMF8 PLXNA3 ADAMTSL1 NTRK2 PAPLN PKHD1L1 CD200R1 MST1R FCGR3A FCGR3B UNC5C HCFC2	7.83e-04	706	108	12	IPR013783
Domain	IPT	PLXNA3 PKHD1L1 MST1R	8.25e-04	32	108	3	IPR002909
Domain	G-protein_beta_WD-40_rep	NLE1 WDR1 WDR17 FBXW7	1.49e-03	85	108	4	IPR020472
Domain	-	PLXNA3 ADAMTSL1 NTRK2 PAPLN PKHD1L1 CD200R1 MST1R FCGR3A FCGR3B UNC5C HCFC2	1.58e-03	663	108	11	2.60.40.10
Domain	DUF4599	SPATA31D4 SPATA31D3	2.11e-03	12	108	2	PF15371
Domain	DUF4599	SPATA31D4 SPATA31D3	2.11e-03	12	108	2	IPR027970
Domain	PLAC	ADAMTSL1 PAPLN	2.88e-03	14	108	2	PF08686
Domain	Sushi	CD46 C4BPA CSMD1	3.38e-03	52	108	3	PF00084
Domain	CCP	CD46 C4BPA CSMD1	3.76e-03	54	108	3	SM00032
Domain	SUSHI	CD46 C4BPA CSMD1	4.17e-03	56	108	3	PS50923
Domain	Sushi_SCR_CCP_dom	CD46 C4BPA CSMD1	4.39e-03	57	108	3	IPR000436
Domain	Furin_repeat	ERBB2 FRAS1	4.77e-03	18	108	2	IPR006212
Domain	FU	ERBB2 FRAS1	4.77e-03	18	108	2	SM00261
Domain	PLAC	ADAMTSL1 PAPLN	5.31e-03	19	108	2	PS50900
Domain	PLAC	ADAMTSL1 PAPLN	5.31e-03	19	108	2	IPR010909
Pubmed	IL-17C regulates the innate immune function of epithelial cells in an autocrine manner.	RAG2 IL17RE IL17RA	6.63e-07	6	113	3	21993848
Pubmed	Functional genetic analysis of mouse chromosome 11.	ERBB2 NLE1 WDR1 MED13	8.92e-07	23	113	4	12955145
Pubmed	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.	RAG2 FCGR3A FCGR3B	9.33e-06	13	113	3	26787820
Pubmed	Human Fc gamma RIII: cloning, expression, and identification of the chromosomal locus of two Fc receptors for IgG.	FCGR3A FCGR3B	1.05e-05	2	113	2	2521732
Pubmed	PP1 promotes cyclin B destruction and the metaphase-anaphase transition by dephosphorylating CDC20.	PPA1 CDC20	1.05e-05	2	113	2	32755477
Pubmed	Single-cell analyses identify dysfunctional CD16+ CD8 T cells in smokers.	FCGR3A FCGR3B	1.05e-05	2	113	2	33163982
Pubmed	Association study of copy number variants in FCGR3A and FCGR3B gene with risk of ankylosing spondylitis in a Chinese population.	FCGR3A FCGR3B	1.05e-05	2	113	2	26494566
Pubmed	Impact of allele copy number of polymorphisms in FCGR3A and FCGR3B genes on susceptibility to ulcerative colitis.	FCGR3A FCGR3B	1.05e-05	2	113	2	23917248
Pubmed	Evidence for gene recombination in FCGR3 gene variants.	FCGR3A FCGR3B	1.05e-05	2	113	2	19320901
Pubmed	Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes.	FCGR3A FCGR3B	1.05e-05	2	113	2	25966632
Pubmed	The Fc gamma receptor of natural killer cells is a phospholipid-linked membrane protein.	FCGR3A FCGR3B	1.05e-05	2	113	2	2967436
Pubmed	Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C.	F5 PROS1	1.05e-05	2	113	2	8428962
Pubmed	Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout.	RAG2 DMD	1.05e-05	2	113	2	17452104
Pubmed	Identification and functional characterization of a novel interleukin 17 receptor: a possible mitogenic activation through ras/mitogen-activated protein kinase signaling pathway.	IL17RE IL17RA	1.05e-05	2	113	2	16310341
Pubmed	Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation.	F5 PROS1	1.05e-05	2	113	2	26251307
Pubmed	Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.	F5 PROS1	1.05e-05	2	113	2	23892573
Pubmed	Somatic mutations of the CDC4 (FBXW7) gene in hereditary colorectal tumors.	CDC40 FBXW7	1.05e-05	2	113	2	19420964
Pubmed	Charge variant analysis of proposed biosimilar to Trastuzumab.	ERBB2 FCGR3A	1.05e-05	2	113	2	28087106
Pubmed	Cloning and sequencing of a cDNA encoding the murine vitamin K-dependent protein S.	C4BPA PROS1	1.05e-05	2	113	2	8148380
Pubmed	Low copy numbers of FCGR3A and FCGR3B associated with Chinese patients with SLE and AASV.	FCGR3A FCGR3B	1.05e-05	2	113	2	28355982
Pubmed	The human low affinity immunoglobulin G Fc receptor III-A and III-B genes. Molecular characterization of the promoter regions.	FCGR3A FCGR3B	1.05e-05	2	113	2	7836402
Pubmed	Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.	FCGR3A FCGR3B	1.05e-05	2	113	2	25816339
Pubmed	Mutations in the cofilin partner Aip1/Wdr1 cause autoinflammatory disease and macrothrombocytopenia.	RAG2 WDR1	1.05e-05	2	113	2	17515402
Pubmed	The loss of the CD16 B73.1/Leu11c epitope occurring in some primary immunodeficiency diseases is not associated with the FcgammaRIIIa-48L/R/H polymorphism.	FCGR3A FCGR3B	1.05e-05	2	113	2	20664961
Pubmed	FCGR Genetic Variation in Two Populations From Ecuador Highlands-Extensive Copy-Number Variation, Distinctive Distribution of Functional Polymorphisms, and a Novel, Locally Common, Chimeric FCGR3B/A (CD16B/A) Gene.	FCGR3A FCGR3B	1.05e-05	2	113	2	34108956
Pubmed	The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex.	F5 PROS1	1.05e-05	2	113	2	31364267
Pubmed	The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.	FCGR3A FCGR3B	1.05e-05	2	113	2	23770975
Pubmed	In vivo clearance of human protein S in a mouse model: influence of C4b-binding protein and the Heerlen polymorphism.	C4BPA PROS1	1.05e-05	2	113	2	16100035
Pubmed	Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis.	FCGR3A FCGR3B	1.05e-05	2	113	2	22290871
Pubmed	Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.	FCGR3A FCGR3B	1.05e-05	2	113	2	20980704
Pubmed	Nucleotide sequence of a new Fc gamma receptor IIIB allele that codes for a neutrophil antigen.	FCGR3A FCGR3B	1.05e-05	2	113	2	11034564
Pubmed	C-terminal residues 621-635 of protein S are essential for binding to factor Va.	F5 PROS1	1.05e-05	2	113	2	10593904
Pubmed	Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.	ERBB2 FCGR3A	1.05e-05	2	113	2	27378608
Pubmed	Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases.	ERBB2 NTRK2	1.05e-05	2	113	2	28446206
Pubmed	MYBL2 in synergy with CDC20 promotes the proliferation and inhibits apoptosis of gastric cancer cells.	CDC20 MYBL2	1.05e-05	2	113	2	34358419
Pubmed	Separate promoters from proximal and medial control regions contribute to the natural killer cell-specific transcription of the human FcgammaRIII-A (CD16-A) receptor gene.	FCGR3A FCGR3B	1.05e-05	2	113	2	8940055
Pubmed	Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system.	C4BPA PROS1	1.05e-05	2	113	2	1833851
Pubmed	FCGR3A and FCGR3B copy number variations are risk factors for sarcoidosis.	FCGR3A FCGR3B	1.05e-05	2	113	2	27059607
Pubmed	Association of FCGR3A and FCGR3B copy number variations with systemic lupus erythematosus and rheumatoid arthritis in Taiwanese patients.	FCGR3A FCGR3B	1.05e-05	2	113	2	25154742
Pubmed	A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms.	FCGR3A FCGR3B	1.05e-05	2	113	2	2525780
Pubmed	FcgammaRIII expression on cultured human keratinocytes and upregulation by interferon-gamma.	FCGR3A FCGR3B	1.05e-05	2	113	2	12445195
Pubmed	Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions.	FCGR3A FCGR3B	1.05e-05	2	113	2	2526846
Pubmed	B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.	FCGR3A FCGR3B	1.05e-05	2	113	2	18292508
Pubmed	In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16.	ERBB2 FCGR3A	1.05e-05	2	113	2	18787406
Pubmed	hLodestar/HuF2 interacts with CDC5L and is involved in pre-mRNA splicing.	TTF2 MATR3 MYBL2	1.48e-05	15	113	3	12927788
Pubmed	Fc gamma receptor genes as risk markers for localized aggressive periodontitis in African-Americans.	FCGR3A FCGR3B	3.13e-05	3	113	2	12027254
Pubmed	Novel APC-cleavage sites in FVa provide insights into mechanisms of action of APC and its cofactor protein S.	F5 PROS1	3.13e-05	3	113	2	19874463
Pubmed	Analysis of Fc gamma RIII (CD16) membrane expression and association with CD3 zeta and Fc epsilon RI-gamma by site-directed mutation.	FCGR3A FCGR3B	3.13e-05	3	113	2	1825220
Pubmed	Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease.	FCGR3A FCGR3B	3.13e-05	3	113	2	16133986
Pubmed	Association between Fcγ receptor IIA, IIIA and IIIB genetic polymorphisms and susceptibility to severe malaria anemia in children in western Kenya.	FCGR3A FCGR3B	3.13e-05	3	113	2	28427365
Pubmed	Different stabilities of the structurally related receptors for IgE and IgG on the cell surface are determined by length of the stalk region in their alpha-chains.	FCGR3A FCGR3B	3.13e-05	3	113	2	16709862
Pubmed	Patterns of low-affinity immunoglobulin receptor polymorphisms in stroke and homozygous sickle cell disease.	FCGR3A FCGR3B	3.13e-05	3	113	2	11835346
Pubmed	FcgammaRIIa, IIIa and IIIb gene polymorphisms in Behçet's disease: do they have any clinical implications?	FCGR3A FCGR3B	3.13e-05	3	113	2	19026120
Pubmed	Immunoglobulin G fc-receptor (FcgammaR) IIA, IIIA, and IIIB polymorphisms related to disease severity in rheumatoid arthritis.	FCGR3A FCGR3B	3.13e-05	3	113	2	12064825
Pubmed	FcgammaRIIA, FcgammaRIIIA and FcgammaRIIIB polymorphisms in Spanish patients with systemic lupus erythematosus.	FCGR3A FCGR3B	3.13e-05	3	113	2	12121275
Pubmed	Infectious complications after chemotherapy and stem cell transplantation in multiple myeloma: implications of Fc gamma receptor and myeloperoxidase promoter polymorphisms.	FCGR3A FCGR3B	3.13e-05	3	113	2	18452102
Pubmed	Fcgamma receptor polymorphisms in relation to periodontitis.	FCGR3A FCGR3B	3.13e-05	3	113	2	12834496
Pubmed	Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells.	MST1R SMAD4	3.13e-05	3	113	2	18310076
Pubmed	Fc gamma RIIa, IIIa and IIIb polymorphisms in Turkish children susceptible to recurrent infectious diseases.	FCGR3A FCGR3B	3.13e-05	3	113	2	16550341
Pubmed	Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients.	FCGR3A FCGR3B	3.13e-05	3	113	2	14597109
Pubmed	Genetic polymorphism of Fcγ-receptors IIa, IIIa and IIIb in South Indian patients with generalized aggressive periodontitis.	FCGR3A FCGR3B	3.13e-05	3	113	2	22167032
Pubmed	Polymorphisms of Immunoglobulin G Fc Receptors in Pediatric Guillain-Barré Syndrome.	FCGR3A FCGR3B	3.13e-05	3	113	2	27064330
Pubmed	Significant differences in FcγRIIa, FcγRIIIa and FcγRIIIb genes polymorphism and anti-malarial IgG subclass pattern are associated with severe Plasmodium falciparum malaria in Saudi children.	FCGR3A FCGR3B	3.13e-05	3	113	2	34551786
Pubmed	FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.	FCGR3A FCGR3B	3.13e-05	3	113	2	26314337
Pubmed	Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease.	FCGR3A FCGR3B	3.13e-05	3	113	2	19946017
Pubmed	Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms.	FCGR3A FCGR3B	3.13e-05	3	113	2	12176802
Pubmed	No association of Fc gamma RIIa, Fc gamma RIIIa and Fc gamma RIIIb polymorphisms with MS.	FCGR3A FCGR3B	3.13e-05	3	113	2	12864991
Pubmed	Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors.	NPY4R2 NPY4R	3.13e-05	3	113	2	8643460
Pubmed	Genetic Variants That Are Associated with Neuropsychiatric Systemic Lupus Erythematosus.	FCGR3A FCGR3B	3.13e-05	3	113	2	26773105
Pubmed	A novel functional assay of protein C in human plasma and its comparison with amidolytic and anticoagulant assays.	F5 PROS1	3.13e-05	3	113	2	1615482
Pubmed	Sertoli Cells Improve Myogenic Differentiation, Reduce Fibrogenic Markers, and Induce Utrophin Expression in Human DMD Myoblasts.	ERBB2 DMD	3.13e-05	3	113	2	34680138
Pubmed	Association of Fcgamma receptor IIa genotype with chronic periodontitis in Caucasians.	FCGR3A FCGR3B	3.13e-05	3	113	2	15152814
Pubmed	Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes.	FCGR3A FCGR3B	3.13e-05	3	113	2	25775045
Pubmed	The Fc gamma receptor genotype as a severity factor for chronic periodontitis in Japanese patients.	FCGR3A FCGR3B	3.13e-05	3	113	2	11699473
Pubmed	Associations between FCGR3A polymorphisms and susceptibility to rheumatoid arthritis: a metaanalysis.	FCGR3A FCGR3B	3.13e-05	3	113	2	18843786
Pubmed	Absence of association between the Fc gamma receptor IIIA-176F/V polymorphism and the severity of malaria in Thai.	FCGR3A FCGR3B	3.13e-05	3	113	2	12501257
Pubmed	Polymorphisms of Fc gamma-receptors RIIa, RIIIa, and RIIIb in patients with adult periodontal diseases.	FCGR3A FCGR3B	3.13e-05	3	113	2	11528518
Pubmed	Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery disease.	FCGR3A FCGR3B	3.13e-05	3	113	2	15910853
Pubmed	Role of activating FcγR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response.	FCGR3A FCGR3B	3.13e-05	3	113	2	22565545
Pubmed	Associations between FCGR2A rs1801274, FCGR3A rs396991, FCGR3B NA1/NA2 polymorphisms and periodontitis: a meta-analysis.	FCGR3A FCGR3B	3.13e-05	3	113	2	23649770
Pubmed	Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.	ERBB2 FCGR3A	3.13e-05	3	113	2	26450443
Pubmed	Fcgamma receptor polymorphisms and their association with periodontal disease: a meta-analysis.	FCGR3A FCGR3B	3.13e-05	3	113	2	20149216
Pubmed	Risk of periodontitis in systemic lupus erythematosus is associated with Fcgamma receptor polymorphisms.	FCGR3A FCGR3B	3.13e-05	3	113	2	12710759
Pubmed	Cutting edge: intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through FcγRIIIA-dependent mechanisms.	FCGR3A FCGR3B	3.13e-05	3	113	2	21317388
Pubmed	Allelic and copy-number variations of FcγRs affect granulocyte function and susceptibility for autoimmune blistering diseases.	FCGR3A FCGR3B	3.13e-05	3	113	2	26032265
Pubmed	Association study of copy number variants in CCL3L1, FCGR3A and FCGR3B genes with risk of ankylosing spondylitis in a West Algerian population.	FCGR3A FCGR3B	3.13e-05	3	113	2	31433132
Pubmed	Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?	FCGR3A FCGR3B	3.13e-05	3	113	2	16160618
Pubmed	Susceptibility to Plasmodium falciparum Malaria: Influence of Combined Polymorphisms of IgG3 Gm Allotypes and Fc Gamma Receptors IIA, IIIA, and IIIB.	FCGR3A FCGR3B	3.13e-05	3	113	2	33424858
Pubmed	FcgammaRIIA and FcgammaRIIIB mediate nuclear factor activation through separate signaling pathways in human neutrophils.	FCGR3A FCGR3B	3.13e-05	3	113	2	19342628
Pubmed	The role of fcgamma receptor gene polymorphism in pediatric renal transplant rejections.	FCGR3A FCGR3B	3.13e-05	3	113	2	19100392
Pubmed	HIV-1 Tat inhibits human natural killer cell function by blocking L-type calcium channels.	FCGR3A FCGR3B	3.13e-05	3	113	2	9743356
Pubmed	Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients.	FCGR3A FCGR3B	3.13e-05	3	113	2	17710620
Pubmed	Association of rheumatoid factor production with FcgammaRIIIa polymorphism in Taiwanese rheumatoid arthritis.	FCGR3A FCGR3B	3.13e-05	3	113	2	16542359
Pubmed	IL-17 Receptor Signaling in the Lung Epithelium Is Required for Mucosal Chemokine Gradients and Pulmonary Host Defense against K. pneumoniae.	IL17RE IL17RA	3.13e-05	3	113	2	27923703
Pubmed	SMAD4 Loss Induces c-MYC-Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis.	NLE1 SMAD4	3.13e-05	3	113	2	36219392
Pubmed	Role of IL-17A and neutrophils in fibrosis in experimental hypersensitivity pneumonitis.	RAG2 IL17RA	3.13e-05	3	113	2	23453796
Pubmed	Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms.	FCGR3A FCGR3B	3.13e-05	3	113	2	15833371
Pubmed	Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.	ERBB2 FCGR3A	3.13e-05	3	113	2	23780683
Pubmed	Fcgamma receptor IIIA polymorphism as a risk factor for acute poliomyelitis.	FCGR3A FCGR3B	3.13e-05	3	113	2	12447772
Pubmed	BARD1 regulates BRCA1-mediated transactivation of the p21WAF1/CIP1 and Gadd45 promoters.	BARD1 GADD45A	3.13e-05	3	113	2	18243530
Cytoband	1q23	F5 FCGR3A FCGR3B	2.48e-05	23	113	3	1q23
GeneFamily	WD repeat domain containing	MED16 NBEAL1 BCAS3 CDC40 DCAF10 NLE1 CORO6 IFT80 WDR1 CDC20 WDR17 FBXW7	1.68e-09	262	80	12	362
GeneFamily	ADAMTS like	ADAMTSL1 PAPLN	4.00e-04	7	80	2	947
GeneFamily	Endogenous ligands\|Minor histocompatibility antigens	ERBB2 P2RX5 PRCP	1.49e-03	51	80	3	870
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	SLAMF8 ERBB2 CD46 MST1R FCGR3A FCGR3B IL17RA	1.79e-03	394	80	7	471
GeneFamily	Integrator complex	INTS3 INTS5	1.96e-03	15	80	2	1366
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	CD46 C4BPA CSMD1	2.06e-03	57	80	3	1179
ToppCell	Control-Control-Lymphocyte-T/NK-NK_activated\|Control / Disease, condition lineage and cell class	ERBB2 ZNF772 ZCCHC2 NT5M FCGR3A FCGR3B MACF1 CARD11	4.21e-08	198	113	8	76d5fe4e5bbe6c73a6ca409b80b5c3924e07cab7
ToppCell	Control_saline-Epithelial_alveolar-AT_1-Differentiating_AT1\|Control_saline / Treatment groups by lineage, cell group, cell type	ERBB2 FRAS1 SELENBP1 NBEAL1 MAGI3 IL17RE IFT80	7.49e-07	198	113	7	85f424cd9bb3117c9e322031024aabb87696ce47
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ERBB2 FRAS1 NBEAL1 LMNTD2 MAGI3 IL17RE IFT80	7.74e-07	199	113	7	d43c605a4ff221cf78d91678c15d2ad20f831c7f
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ERBB2 FRAS1 SELENBP1 NBEAL1 MAGI3 IL17RE IFT80	8.01e-07	200	113	7	ddfb1f006365bf16203ee49f20200f68220cc288
ToppCell	control-HLA-DR-_S100A+_Monocyte\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	RNF130 TMEM144 ROGDI F5 GASK1B IL17RA FZD2	8.01e-07	200	113	7	107a0665fb20247511a430178effd7630a619488
ToppCell	BAL-Severe-cDC_4\|Severe / Compartment, Disease Groups and Clusters	SELENBP1 PARP8 F5 NT5M CORO6 CSMD1	3.16e-06	158	113	6	73f66689ef59f71b14cb7141ca5951cc47fe57c1
ToppCell	Transplant_Alveoli_and_parenchyma-Epithelial-Basal_1\|Transplant_Alveoli_and_parenchyma / Tissue, Lineage and Cell class of Lung Cells from 10X	RIPK4 CLEC4G KIAA1958 FBXO32 CDC20 ANAPC7	4.82e-06	170	113	6	aabe993c9f337b1caaeb0e64626a3920579c41b7
ToppCell	droplet-Lung-nan-21m-Myeloid-classical_monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLAMF8 RNF130 F5 FCGR3B PRCP IL17RA	5.33e-06	173	113	6	9019049b1e2a24cb0bbbc620d64ef29dd18cc4c6
ToppCell	droplet-Lung-nan-21m-Myeloid-Classical_Monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLAMF8 RNF130 F5 FCGR3B PRCP IL17RA	5.33e-06	173	113	6	077029eecfe636a5baf5f70464e1713b3f6b4274
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Macrophage_Dendritic-Cycling_Mononuclear_Phagocyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	SLAMF8 TTF2 BARD1 CD200R1 CDC20 MYBL2	5.51e-06	174	113	6	7b318796728001c17b4043d2b033330c7be40c78
ToppCell	PBMC-Mild-cDC_11\|Mild / Compartment, Disease Groups and Clusters	SLAMF8 STK17A PPM1J GCSAM ZC3HAV1L DMD	6.07e-06	177	113	6	974305e4c0eff90134c4e58cf11b955d1eee0501
ToppCell	PND28-Mesenchymal-Mesenchymal_structural-Fibroblastic-Mesothelial-Mesothelial_mature\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	FRAS1 PAPLN PKHD1L1 MST1R NPY4R IL17RE	6.90e-06	181	113	6	330d4322f4c4373f706273c1f4e218b59051b7fd
ToppCell	PND28-Mesenchymal-Mesenchymal_structural-Fibroblastic-Mesothelial\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	FRAS1 PAPLN PKHD1L1 MST1R NPY4R IL17RE	6.90e-06	181	113	6	3f4d5d79c1286614514b0e8134079d6128a2a23e
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Neuronal-Glial_immature\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RNF130 FRAS1 STK17A SHC4 DMD FBXW7	7.12e-06	182	113	6	ecb5624c9074cc6449fad961df54c926c2681d54
ToppCell	severe-Myeloid-Neutrophils_3\|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	CD46 F5 ABHD5 FCGR3B C4BPA IL17RA	9.95e-06	193	113	6	f4d43dfbf4115dd0f843ea5cf08049220342a047
ToppCell	severe-Myeloid-Neutrophils_3\|severe / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	CD46 F5 ABHD5 FCGR3B C4BPA IL17RA	1.02e-05	194	113	6	1f8edab1c8ba48bc0114429ea47aab378b5830b7
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic-neutrophil\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ADAMTSL1 NTRK2 F5 FCGR3B IL17RA CSMD1	1.06e-05	195	113	6	d3755929ebbbf5e3afde44281e9056ddb614a291
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ADAMTSL1 NTRK2 F5 FCGR3B IL17RA CSMD1	1.06e-05	195	113	6	19853c654ac64b3ae3bc99841c6cb29c8aaba85c
ToppCell	healthy_donor-Lymphocytic-ILC-NK_cell\|healthy_donor / Disease condition, Lineage, Cell class and subclass	ERBB2 PARP8 FCGR3A FCGR3B MACF1 CARD11	1.15e-05	198	113	6	d7053a898e04478c577381085f615edaad3cdc5b
ToppCell	healthy_donor-Lymphocytic-ILC\|healthy_donor / Disease condition, Lineage, Cell class and subclass	ERBB2 PARP8 FCGR3A FCGR3B MACF1 CARD11	1.15e-05	198	113	6	aa33be29e26f1b8facfc894413099083ae3bbb1b
ToppCell	COVID_non-vent-Lymphocytic-ILC\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	ERBB2 PARP8 FCGR3A FCGR3B MACF1 CARD11	1.18e-05	199	113	6	df4f7d5be099e3e6054f3b812ccf70251664e4c0
ToppCell	control-cDC\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	SLAMF8 RNF130 ROGDI CD200R1 PRCP FZD2	1.18e-05	199	113	6	31825ba336603fe940dea6022e18ec25af110f4c
ToppCell	Transverse-NK_cell\|Transverse / Region, Cell class and subclass	CCNJL STK17A PARP8 FCGR3A FCGR3B ITGB1BP2	1.18e-05	199	113	6	6d5d57addfed3947408b9af7d6aa78aaa3197f94
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_1\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ERBB2 FRAS1 SELENBP1 MAGI3 IL17RE IFT80	1.18e-05	199	113	6	1c70e7d6bd25980e1b92aa1cac3f3c95d9651b4b
ToppCell	Transverse-(0)_NK_cell-(00)_NK\|Transverse / shred on region, Cell_type, and subtype	CCNJL STK17A PARP8 FCGR3A FCGR3B ITGB1BP2	1.18e-05	199	113	6	b649375394bc55b8727814283defed711e899e9c
ToppCell	COVID_non-vent-Lymphocytic-ILC-NK_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	ERBB2 PARP8 FCGR3A FCGR3B MACF1 CARD11	1.18e-05	199	113	6	ed35d747f11f6ea6a5cb7061057f0a98d9e0db99
ToppCell	wk_08-11-Epithelial-Airway_epithelial_progenitor\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	FRAS1 ADAMTSL1 MAGI3 RIPK4 IL17RE DMD	1.18e-05	199	113	6	af664e0d41a889a75dbf6cf0d50acd26f5ab3a3a
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	ERBB2 STK17A FCGR3A FCGR3B MACF1 CARD11	1.18e-05	199	113	6	eb05ccae5187e4701bbbe6d714a6d2808fbcf306
ToppCell	PBMC-Control-Lymphocyte-T/NK-NK_cell\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	CCNJL ERBB2 STK17A FCGR3A FCGR3B MACF1	1.18e-05	199	113	6	10c8729b779073c3bf808e85958d59147f0be5c5
ToppCell	Transverse-NK_cell-NK\|Transverse / Region, Cell class and subclass	CCNJL STK17A PARP8 FCGR3A FCGR3B ITGB1BP2	1.18e-05	199	113	6	418e936d3528b6672ab54f77919588e4ed01a8d2
ToppCell	Transverse-(0)_NK_cell\|Transverse / shred on region, Cell_type, and subtype	CCNJL STK17A PARP8 FCGR3A FCGR3B ITGB1BP2	1.18e-05	199	113	6	1970a85893b87eca18916df2504c5148fcd9ceb2
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_1\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ERBB2 FRAS1 LMNTD2 MAGI3 IL17RE IFT80	1.22e-05	200	113	6	8683445ad5b70748c4a1f12eb77d47623085147e
ToppCell	Sepsis-Bac-SEP-Myeloid-cDC1\|Bac-SEP / Disease, condition lineage and cell class	SLAMF8 PPA1 GCSAM CFAP20DC KIAA1958 DMD	1.22e-05	200	113	6	cd381644fd8b8674a017d267bfbb00f2668294ae
ToppCell	COVID-19-COVID-19_Mild-Lymphocyte-T/NK-NK_activated\|COVID-19_Mild / Disease, condition lineage and cell class	ERBB2 PARP8 FCGR3A FCGR3B MACF1 CARD11	1.22e-05	200	113	6	2281debd86e5d92e8fe0397aec9ef670800f7471
ToppCell	PBMC-Control-Myeloid-Neutrophil-Neutrophil-Neu_0\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CCNJL UGT3A1 FCGR3B UNC5C FAM157B	1.89e-05	128	113	5	58639cfdc70ff6764adcc5c1ce9eba9d033b8209
ToppCell	PBMC-Control-Myeloid-Neutrophil-Neutrophil-Neu_0\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CCNJL UGT3A1 FCGR3B UNC5C FAM157B	1.89e-05	128	113	5	9b3c57d559a5ed8d590dd89b64a57a3227d8c684
ToppCell	COVID-19_Mild-Classical_Monocyte-\|Classical_Monocyte / Disease condition and Cell class	SLAMF8 SELENBP1 CFAP20DC FAM157B BRICD5	1.96e-05	129	113	5	23b07c71142979d2178fd3a3cdeb3cde73c72c3d
ToppCell	COVID-19_Mild-Classical_Monocyte-\|COVID-19_Mild / Disease condition and Cell class	SLAMF8 SELENBP1 CFAP20DC FAM157B BRICD5	2.11e-05	131	113	5	ae5eb9c013674b36987bf26d4f752dbb374f547b
ToppCell	PBMC-Mild-Myeloid-Classical_Monocyte-Classical_Monocyte-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	SLAMF8 SELENBP1 CFAP20DC FAM157B BRICD5	2.44e-05	135	113	5	7e3c840b40c41715ff7120a88b8b3f223df4f25a
ToppCell	COVID-19_Mild\|World / 5 Neutrophil clusters in COVID-19 patients	MATR3 ZCCHC2 FCGR3A FAM157B CSMD1	4.31e-05	152	113	5	2ff0980dfd8d430cca14649151d856edef115720
ToppCell	10x5'-Liver-Lymphocytic_T_CD4-Tfh\|Liver / Manually curated celltypes from each tissue	LMNTD2 CFAP20DC CLEC4G FBXO32 BRICD5	4.88e-05	156	113	5	85bc34ff507f9a66c6e3ba7a3ffd5416d0073ccf
ToppCell	PND28-Immune-Immune_Myeloid-Monocytic-Macrophage-AM-AM_mature\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TTF2 CD200R1 FCGR3A CORO6 CARD11	5.18e-05	158	113	5	6811dc4f101dfa9a9cc13d949760d43aa522bf3b
ToppCell	PBMC-Severe-cDC_1\|Severe / Compartment, Disease Groups and Clusters	MATR3 ZNF772 FCGR3B WDR17	5.41e-05	81	113	4	6d1e524f000b71c935359afc801a1d31f218fec8
ToppCell	droplet-Lung-nan-3m-Myeloid-Proliferating_Dendritic\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BARD1 INTS3 GCSAM P2RX5 CLEC4G	5.50e-05	160	113	5	8a7a73b0ee1877fe02d47f745d36ae2858b529e1
ToppCell	droplet-Fat-Gat-18m-Myeloid-nan\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLAMF8 GCSAM FCGR3B PRCP CLEC4G	5.84e-05	162	113	5	052f797d8bcab8fc6a43e0bffdd215c88ee12889
ToppCell	droplet-Lung-21m-Hematologic-myeloid-intermediate_monocyte\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SLAMF8 RNF130 F5 FCGR3B IL17RA	6.19e-05	164	113	5	cd0794f84dfd346807e2d803723718b7f22e9232
ToppCell	droplet-Lung-21m-Hematologic-myeloid-intermediate_monocyte-intermediate_monocyte_l4\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SLAMF8 RNF130 F5 FCGR3B IL17RA	6.19e-05	164	113	5	12251a49fd4af32d4edb58046245548c260cf04b
ToppCell	facs-MAT-Fat-3m-Myeloid-macrophage\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLAMF8 CD200R1 FCGR3B PRCP CLEC4G	6.19e-05	164	113	5	b81498c3934e0d52bf0329dc745e02966f9d8613
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-DC-DC1-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	TRIM61 PPM1J GCSAM CARD11 MYBL2	6.55e-05	166	113	5	c8a7d94ed762e5e045ab5f74eef691ddc5f74993
ToppCell	droplet-Lung-30m-Hematologic-myeloid-myeloid_dendritic_cell\|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SLAMF8 ROGDI GCSAM P2RX5 CARD11	7.13e-05	169	113	5	b2d53159e344fad6fcdc485d5b8f6cf1bf094b1f
ToppCell	droplet-Lung-1m-Hematologic-myeloid-myeloid_dendritic_cell-proliferating_dendritic\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PLXNA3 GCSAM URB1 CDC20 MYBL2	7.33e-05	170	113	5	badbe200e9d5003d23d115955b10b4ea767f6c26
ToppCell	droplet-Spleen-SPLEEN-1m-Hematologic\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLAMF8 SELENBP1 MST1R FCGR3A FCGR3B	7.33e-05	170	113	5	7cb7ad9ab064b6ea452545d145e5b1d4090cd4c1
ToppCell	droplet-Spleen-SPLEEN-1m-Hematologic-nan\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLAMF8 SELENBP1 MST1R FCGR3A FCGR3B	7.33e-05	170	113	5	db7cee7e518debb2cbe9eeae05d47e14b69cb8e3
ToppCell	facs-Lung-EPCAM-24m-Myeloid-Myeloid_Dendritic_Type_1\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLAMF8 ROGDI CD200R1 CLEC4G CARD11	7.75e-05	172	113	5	cabe7b4131d72da87d3caacd8cced3a4f2cbef53
ToppCell	367C-Lymphocytic-ILC-ILC-2\|367C / Donor, Lineage, Cell class and subclass (all cells)	STK17A PARP8 HIC2 NT5M GCSAM	7.96e-05	173	113	5	0451450605521fecb27a958628870d268adfb023
ToppCell	Bac-SEP-Myeloid-cDC1\|Bac-SEP / Disease, Lineage and Cell Type	SLAMF8 GCSAM CFAP20DC KIAA1958 DMD	7.96e-05	173	113	5	f88269327441858ddb8c49b9dd619b76fd53b1da
ToppCell	URO-Myeloid-cDC1\|URO / Disease, Lineage and Cell Type	SLAMF8 PPA1 PPM1J GCSAM DMD	7.96e-05	173	113	5	57f4e9f39ef6e02dca76f3dd0b39a0871917ed5a
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-B_cells-Cycling_B_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	GCSAM CFAP20DC P2RX5 CDC20 MYBL2	7.96e-05	173	113	5	b7e0193fd4983cb38d1bee441f608f73ee8743b9
ToppCell	droplet-Lung-nan-21m-Myeloid\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SLAMF8 RNF130 FCGR3B PRCP IL17RA	8.18e-05	174	113	5	763ca53339d9e236da8463f2a9d1bd39d4385d75
ToppCell	systemic_lupus_erythematosus-managed-Lymphocytic_B-plasmablast-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	PKHD1L1 P2RX5 CPT1C CDC20 MYBL2	8.40e-05	175	113	5	89bf89466191da14896ed8928027f5b911436c22
ToppCell	PBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MATR3 RETREG3 FCGR3A FCGR3B MACF1	8.87e-05	177	113	5	d3e6c768b88b7906f3c7fdd00ba20842212c14b1
ToppCell	PBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MATR3 RETREG3 FCGR3A FCGR3B MACF1	8.87e-05	177	113	5	f8f101c772c043636bedd6b2ec81409b1d2599bf
ToppCell	Adult-Epithelial-club_cell-D175\|Adult / Lineage, Cell type, age group and donor	CCNJL FRAS1 SHC4 NT5M C4BPA	8.87e-05	177	113	5	d652b7d84fe6aa38319d8d5adc72c70441bd0088
ToppCell	COVID-19_Mild-Lymphoid_T/NK-NK_activated\|COVID-19_Mild / Disease group, lineage and cell class	MATR3 RETREG3 FCGR3A FCGR3B MACF1	8.87e-05	177	113	5	6978a22fef40c8b455342373abe7593f5ede0fa4
ToppCell	-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	PKHD1L1 GCSAM P2RX5 MYBL2 FBXW7	8.87e-05	177	113	5	ae2d2e138946535596fa30a55207f261cafda461
ToppCell	PBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	MATR3 RETREG3 FCGR3A FCGR3B MACF1	8.87e-05	177	113	5	936ab2b180a052387124f68d0c7f41c0b164e748
ToppCell	PBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	MATR3 RETREG3 FCGR3A FCGR3B MACF1	8.87e-05	177	113	5	d5aeda113afaa2425874394610344570c9078478
ToppCell	droplet-Spleen-nan-21m-Lymphocytic-immature_NKT_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHC4 CFAP20DC CPT1C ZC3HAV1L CDC20	9.35e-05	179	113	5	dabecd283c1f0f71a66b804c99be8bd48ea36e35
ToppCell	Control-Fibroblasts-Airway_smooth_muscle\|Control / group, cell type (main and fine annotations)	ADAMTSL1 NTRK2 UNC5C FBXO32 DMD	9.60e-05	180	113	5	d0de12749ef0f51f0931c6e7b9b99966bdbc3ec1
ToppCell	3'-Pediatric_IBD-SmallIntestine-Hematopoietic-Myeloid-cDC1\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SLAMF8 ROGDI PPA1 PPM1J GCSAM	9.85e-05	181	113	5	84ca8c9c036478a6d3a2071919d09065455d417c
ToppCell	Frontal_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2-Fezf2\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	BARD1 NPY4R ITGB1BP2 CARD11	1.01e-04	95	113	4	ffbf3e362384c87b9db690ed39cd215e1f68375c
ToppCell	T_cells-Resident_memory_CD8+_T_cells\|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis	SLAMF8 NBEAL1 STK17A PARP8 PACS2	1.01e-04	182	113	5	111d434b89902ec11fb07f41b8ee1a98f3991b61
ToppCell	COVID-19_Mild-gd_T\|COVID-19_Mild / Disease condition and Cell class	PARP8 MATR3 FCGR3A FCGR3B MACF1	1.04e-04	183	113	5	f593a89b0aa8fffdfa403769916facfd30358521
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-T_cells-NK_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	STK17A PARP8 FCGR3A FCGR3B CARD11	1.04e-04	183	113	5	b902390614fe924d48511e4187b36a0b49b08f23
ToppCell	COVID-19_Mild-NK_activated\|COVID-19_Mild / Disease condition and Cell class	MATR3 RETREG3 FCGR3A FCGR3B MACF1	1.04e-04	183	113	5	22bd05135906d0ecc4ba8c2e0a666093d1bf3b8f
ToppCell	3'-GW_trimst-2-SmallIntestine-Hematopoietic-B_cells-Pre-B\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RAG2 GCSAM P2RX5 CARD11 MYBL2	1.04e-04	183	113	5	32880e71adba1b63fa9ec8530a8d4e46cc277c3a
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRAS1 NEB PKHD1L1 DMD CSMD1	1.06e-04	184	113	5	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRAS1 NEB PKHD1L1 DMD CSMD1	1.06e-04	184	113	5	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FRAS1 NEB PKHD1L1 DMD CSMD1	1.06e-04	184	113	5	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	CV-Moderate-7\|Moderate / Virus stimulation, Condition and Cluster	TTF2 CD46 URB1 MACF1 IFT80	1.09e-04	185	113	5	a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCell	CV-Moderate-7\|CV / Virus stimulation, Condition and Cluster	TTF2 CD46 URB1 MACF1 IFT80	1.12e-04	186	113	5	8571956890fc9894d766ba294a28e376b4aba428
ToppCell	Healthy-multiplets\|Healthy / disease group, cell group and cell class	SLAMF8 PPM1J PKHD1L1 GCSAM CDC20	1.12e-04	186	113	5	2ec999b97e95afb898f8083042b0f188d3d234bc
ToppCell	390C-Lymphocytic-CD4_T-cell-Treg_cell_3\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	BCAS3 P2RX5 KIAA1958 PACS2 CCDC180	1.12e-04	186	113	5	74eb69a52090f9e2426a47e03a1c478ee0cfec18
ToppCell	390C-Lymphocytic-CD4_T-cell-Treg_cell_3\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	BCAS3 P2RX5 KIAA1958 PACS2 CCDC180	1.15e-04	187	113	5	1eed2c1a05e80a7c8f639437c117afe0c18dfb0c
ToppCell	droplet-Kidney-KIDNEY-30m-Mesenchymal-nan\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTSL1 BARD1 CD46 CSMD1 FZD2	1.21e-04	189	113	5	544d95df910f1b276995624509a7e41b219baca0
ToppCell	5'-Adult-LymphNode-Hematopoietic-T_cells-NK_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	STK17A PARP8 GCSAM FCGR3A CARD11	1.21e-04	189	113	5	5a9c3c61998efc40a5d2042e0f568b52103734a9
ToppCell	10x_3'_v2v3-Non-neoplastic-Vascular-Mural_cell-VLMC-G\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ADAMTSL1 SELENBP1 GASK1B PTH2R FBXO32	1.24e-04	190	113	5	c90410bb47b8da774dee2a3502f667ce9a7c97d9
ToppCell	10x_3'_v2v3-Non-neoplastic-Vascular-Mural_cell-VLMC\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ADAMTSL1 SELENBP1 GASK1B PTH2R FBXO32	1.24e-04	190	113	5	bc44727e8458a02fae95dc5515b708000d2ee8c4
ToppCell	human_hepatoblastoma-Tumor_cells\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	FRAS1 MAGI3 F5 KIAA1958 MED13	1.33e-04	193	113	5	503a979328c68b096680b71359a26f02fafdff35
ToppCell	Parenchymal-NucSeq-Stromal-Chondrocytic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	SLAMF8 RAG2 NTRK2 UNC5C PHF21B	1.33e-04	193	113	5	df4afb4848eb9d7d8d39e5c612919663cbbb2514
ToppCell	Parenchymal-NucSeq-Stromal-Chondrocytic-Chondrocyte\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	SLAMF8 RAG2 NTRK2 UNC5C PHF21B	1.33e-04	193	113	5	ab36d684bde8fe77d11a5188425135328052c58b
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-2M-Radial_glial-gliogenic/outer_RGCs_and_astrocytes\|Organoid-2M / Sample Type, Dataset, Time_group, and Cell type.	SELENBP1 NTRK2 PTH2R PRCP FBXO32	1.36e-04	194	113	5	7c6c0376603e5fcb64814fd6204d153629c2fbf5
ToppCell	PBMC-Control-Myeloid-cDC-cDC-cDC_4\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	RNF130 PPA1 CD200R1 PRCP FZD2	1.36e-04	194	113	5	6af2971d83f5ad6aed16d0ceb8bfc52f3947bc10
ToppCell	Control-Classical_Monocyte\|Control / Disease condition and Cell class	NBEAL1 PARP8 F5 GASK1B IL17RA	1.36e-04	194	113	5	9e33e1b54b4114f9e6981819834bb796ed7192b5
ToppCell	(7)_MNP-(7)_DC_1\|(7)_MNP / Spleen cell shreds - cell class (v1) and cell subclass (v1)	SLAMF8 PPA1 PPM1J GCSAM DMD	1.36e-04	194	113	5	8dbe0188e2af6f14b3b44e5213fbdd581128082f
ToppCell	PBMC-Control-Myeloid-cDC-cDC-cDC_4\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	RNF130 PPA1 CD200R1 PRCP FZD2	1.36e-04	194	113	5	5c60670ec24470225fabaa6071fdb4ef6e579840
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NTRK2 UNC5C CORO6 FBXO32 DMD	1.36e-04	194	113	5	5c3b2b05d1e4f146551fe4c920263d8e6ca34de3
ToppCell	BLOOD--(1)_T_cell-(1)_Activated_T_cells\|(1)_T_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	BARD1 F5 WDR1 CDC20 MYBL2	1.36e-04	194	113	5	6a0cbb9d5c5c4effb02dff654c6c3b184026875c
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NTRK2 UNC5C CORO6 FBXO32 DMD	1.36e-04	194	113	5	ab9cad697f9209d2889bc02b43b502dfeb2ebfef
ToppCell	PBMC-Control\|PBMC / Compartment, Disease Groups and Clusters	ROGDI NBEAL1 CD200R1 FCGR3A CLEC4G	1.40e-04	195	113	5	3cc4afa5f68f28336310d5f80a082cb8d98a5679
Disease	level of low affinity immunoglobulin gamma Fc region receptor III-A in blood serum	FCGR3A FCGR3B	1.28e-05	2	106	2	OBA_2040305
Disease	Septic Phlebitis, Sagittal Sinus	F5 PROS1	3.83e-05	3	106	2	C0751823
Disease	Sagittal Sinus Thrombophlebitis	F5 PROS1	3.83e-05	3	106	2	C0751824
Disease	Lupus Vasculitis, Central Nervous System	FCGR3A FCGR3B	3.83e-05	3	106	2	C0752332
Disease	Lupus Meningoencephalitis	FCGR3A FCGR3B	3.83e-05	3	106	2	C0752334
Disease	Neuropsychiatric Systemic Lupus Erythematosus	FCGR3A FCGR3B	3.83e-05	3	106	2	C0752335
Disease	Sagittal Sinus Thrombosis	F5 PROS1	3.83e-05	3	106	2	C0338575
Disease	neuroblastoma	PARP8 BARD1 MLYCD FBXO32 CSMD1	6.36e-05	116	106	5	EFO_0000621
Disease	low affinity immunoglobulin gamma Fc region receptor II-a/b measurement	FCGR3A FCGR3B	2.65e-04	7	106	2	EFO_0008211
Disease	cerebrospinal fluid clusterin measurement	MAGI3 FAM124A CSMD1	2.71e-04	35	106	3	EFO_0007657
Disease	venous thromboembolism, factor VII measurement	TTF2 F5 C4BPA	3.47e-04	38	106	3	EFO_0004286, EFO_0004619
Disease	Thrombophilia due to thrombin defect	F5 PROS1	3.53e-04	8	106	2	cv:C3160733
Disease	asparaginase-induced acute pancreatitis	NEB CDC20	4.53e-04	9	106	2	EFO_1001507
Disease	plexin-B2 measurement	FCGR3A FCGR3B	4.53e-04	9	106	2	EFO_0021867
Disease	venous thromboembolism, von Willebrand factor measurement	TTF2 F5 C4BPA	4.67e-04	42	106	3	EFO_0004286, EFO_0004629
Disease	RS-10-hydroxywarfarin to RS-warfarin ratio measurement	FRAS1 PRCP UNC5C SMAD4	6.78e-04	110	106	4	EFO_0803335
Disease	Mammary Ductal Carcinoma	ERBB2 SMAD4	6.88e-04	11	106	2	C0021367
Disease	Invasive Ductal Breast Carcinoma	ERBB2 SMAD4	6.88e-04	11	106	2	C1134719
Disease	Thromboembolism	F5 PROS1	8.24e-04	12	106	2	C0040038
Disease	Erythrocyte Mean Corpuscular Hemoglobin Test	MLYCD AGL	9.72e-04	13	106	2	C0369183
Disease	Finding of Mean Corpuscular Hemoglobin	MLYCD AGL	9.72e-04	13	106	2	C1261502
Disease	ovarian cancer (is_implicated_in)	ERBB2 BARD1 SMAD4	1.09e-03	56	106	3	DOID:2394 (is_implicated_in)
Disease	low affinity immunoglobulin gamma Fc region receptor III-B measurement	FCGR3A FCGR3B	1.13e-03	14	106	2	EFO_0008212
Disease	amygdala volume change measurement	PARP8 CSMD1	1.48e-03	16	106	2	EFO_0021490
Disease	Blood Coagulation Disorders	F5 SMAD4	1.48e-03	16	106	2	C0005779
Disease	low affinity immunoglobulin gamma Fc region receptor II-a measurement	FCGR3A FCGR3B	1.68e-03	17	106	2	EFO_0021969
Disease	Ischemic stroke, venous thromboembolism, stroke, Abnormal thrombosis, deep vein thrombosis, pulmonary embolism	TTF2 F5	1.68e-03	17	106	2	EFO_0000712, EFO_0003827, EFO_0003907, EFO_0004286, HP_0001977, HP_0002140
Disease	autoimmune thyroid disease, type 1 diabetes mellitus	MAGI3 QRFPR	1.88e-03	18	106	2	EFO_0006812, MONDO_0005147
Disease	joint damage measurement	CCNJL PARP8 CSMD1	1.91e-03	68	106	3	EFO_0005413
Disease	Malignant Glioma	ERBB2 NTRK2 FBXW7	2.07e-03	70	106	3	C0555198
Disease	mixed gliomas	ERBB2 NTRK2 FBXW7	2.07e-03	70	106	3	C0259783
Disease	colorectal adenoma (is_marker_for)	F5 SMAD4	2.33e-03	20	106	2	DOID:0050860 (is_marker_for)
Disease	prothrombin time measurement	TTF2 F5	2.57e-03	21	106	2	EFO_0008390
Disease	Nasopharyngeal carcinoma	ERBB2 MST1R	2.82e-03	22	106	2	C2931822
Disease	sorbitol measurement	ADAMTSL1 AIPL1	3.08e-03	23	106	2	EFO_0010533
Disease	Carcinoma of lung	ERBB2 NTRK2	3.08e-03	23	106	2	C0684249
Disease	Intrahepatic Cholangiocarcinoma	ERBB2 SMAD4	3.35e-03	24	106	2	C0345905
Disease	airway responsiveness measurement	BCAS3 CSMD1	3.35e-03	24	106	2	EFO_0006897
Disease	Extrahepatic Cholangiocarcinoma	ERBB2 SMAD4	3.35e-03	24	106	2	C3805278

Protein segments in the cluster

Peptide	Gene	Start	Entry
SSVIHCDADSKWNPS	C4BPA	276	P04003
NTHLCFVHTVPWDQL	ERBB2	471	P04626
VDAHSQVCSILWSPH	CDC20	396	Q12834
KDPTEWHVHTCGLAN	AIPL1	111	Q9NZN9
KHFQHIQVCTPWLEA	ALG1	336	Q9BT22
VKDHAGWTPLHEACN	BARD1	456	Q99728
SLHCEWIIEAKPGHS	CSMD1	781	Q96PZ7
KVQEAWVPSQDTHHT	BRICD5	146	Q6PL45
SVSQKDHHCHTWPTT	CCNJL	206	Q8IV13
DHHCHTWPTTCPRKT	CCNJL	211	Q8IV13
SPKQRTSRCWDHHIA	GCSAM	26	Q8N6F7
HETQTTCWDHPKMTE	DMD	3076	P11532
NTKWPTHHCDKDPSQ	CCDC180	1266	Q9P1Z9
PIKSHEVHWETCRTV	CER1	151	O95813
HVPHGAEEAALTCWK	DHX32	521	Q7L7V1
ILTHPWSSSQCAVHH	BCAS3	381	Q9H6U6
PDHSFCDSLWHNITV	NBEAL1	656	Q6ZS30
HRTTEKWNSVADCLP	RAG2	166	P55895
SFHSLPSWIEECKQH	RAB33B	121	Q9H082
KEHICCLEEWTSPVH	QRFPR	196	Q96P65
FHKSCVDPWLSEHCT	RNF130	286	Q86XS8
CHPDDQFTTSILRHW	INTS3	866	Q68E01
SDQHAEPWVVSGCHS	ANAPC7	301	Q9UJX3
TVKNSTCLDDSWIHP	IL17RA	51	Q96F46
KHGEIWVVPNTDHVC	PARP8	801	Q8N3A8
IHEHGTEWASSPCSV	FRAS1	101	Q86XX4
HKGENTETSPHDCEW	HCFC2	266	Q9Y5Z7
CDLPVHSNKEWSQHI	MATR3	296	P43243
SWSDHKHLAQPDTAV	MAGI3	991	Q5TCQ9
THTICDRNHTWLPVS	CD46	76	P15529
GKQLPASCRHDWHQT	ITGB1BP2	211	Q9UKP3
ADKVVCTESWPLAHH	NPY4R	196	P50391
SEEWSCVLNKISTHP	FAM182A	131	Q5T1J6
RHDWHTLCKDLPNAT	IL17RE	306	Q8NFR9
TWHSPCEVLQKISEA	MLYCD	201	O95822
HARTNKAVPEHLCSW	ADAMTSL1	1696	Q8N6G6
PSERCSSHWAAHKDS	FAM124A	446	Q86V42
LQAEPHQHGCWTVTE	ISM2	71	Q6H9L7
ISDPDVRHTWKSNCL	PLXNA3	1706	P51805
VCTLHGHTSWVKNIE	DCAF10	246	Q5QP82
ERSWVSQHCKSLAIP	FZD2	491	Q14332
PHCSESIHRSWDAIN	PRCP	231	P42785
VCHPDCITTIKHWIT	MACF1	2966	O94854
GTVTVKSTCHWEVHN	CD200R1	196	Q8TD46
HHKTVEWGSLPCLNT	LMNTD2	261	Q8IXW0
LAAQWSSHVKHFPIC	PACS2	866	Q86VP3
IPSEHHEAITCLEWD	MED16	76	Q9Y2X0
QVHVEVPKSHWSCGL	PLA2G4E	271	Q3MJ16
LSVEHSWADCPISGH	CPT1C	466	Q8TCG5
KPESGCTEIHHHEWS	GASK1B	351	Q6UWH4
ETVSKSVCAEPWRHQ	FAM157B	311	P0CG42
PKHQELVSCVGWTTA	IFT80	11	Q9P2H3
DLHCVLVTNPHSSQW	GADD45A	121	P24522
WDPETETCLHTLQGH	FBXW7	526	Q969H0
TVEHLAIQCHWSQRP	DDX50	361	Q9BQ39
DDMHPDVIHSVCWNS	CORO6	171	Q6QEF8
EDPIHLRCHSWKNTA	FCGR3B	121	O75015
WSDCISVEHRPGTHD	MARCHF10	421	Q8NA82
ESACTVPTDVDKWFH	PPA1	271	Q15181
EDPIHLRCHSWKNTA	FCGR3A	121	P08637
HILSWKGTDHPCTAN	FBXO32	321	Q969P5
VPLDTCTKEEAHWTI	CARD11	726	Q9BXL7
WNCDLDKAASECHPH	P2RX5	261	Q93086
TPSWEHVLFTACHNQ	NT5M	186	Q9NPB1
DPATLRQHEKTHWLT	HIC2	516	Q96JB3
WDLSTETPHFTCKGH	NLE1	141	Q9NVX2
VSHVHKVECVIPWLN	ROGDI	241	Q9GZN7
TMPDITVCAHDHISW	F5	241	P12259
SHIPAGDCSEHWKTQ	NIN	136	Q8N4C6
HNHLNPEVKKSCWTE	MYBL2	126	P10244
KVCIGAVWHPHETSK	CDC40	551	O60508
AVWHPHETSKVITCG	CDC40	556	O60508
QSIKETPCWIEIHLH	SMAD4	516	Q13485
PQSCWSSQKEVSHES	PPM1J	216	Q5JR12
PNLKDELHHSGWNTC	SELENBP1	66	Q13228
WHSVKQTICLPEKSH	SPATA31D4	851	Q6ZUB0
EHKKTITAISWCPHN	WDR17	81	Q8IZU2
HHAKIVCLAWSPDNE	WDR1	531	O75083
ISTHEHLAWVTCLPE	SEBOX	46	Q9HB31
VDEALVKSSCLHPWS	MED13	1251	Q9UHV7
DTTHSPWHLEASCTL	INTS5	896	Q6P9B9
SKHNDIRAHSCPSVW	PROS1	656	P07225
TWLAIKCSPSLHVDD	RIPK4	46	P57078
WGPAAVEHHKTCRSL	URB1	1566	O60287
TAEECLKHPWLTQSS	STK17A	311	Q9UEE5
TWCPTSISHLKEAEE	ABHD5	26	Q8WTS1
DSCNPSHLWLEASKE	CFAP20DC	321	Q6ZVT6
VPKTTWAAAQDHCAD	CLEC4G	181	Q6UXB4
TSDHHWCIPFTVKGN	NTRK2	296	Q16620
DWRKQSCTTIQHPEH	ZCCHC2	541	Q9C0B9
SVPELCHHVAEVWVS	RETREG3	136	Q86VR2
SHSLPHIKQQLWSEE	SHC4	511	Q6S5L8
LSTDHQHHCVWPIKK	TRIM61	121	Q5EBN2
WHSVKQTICLPEKSH	SPATA31D3	851	P0C874
CQSSHWPRDVHLATN	UGT3A1	331	Q6NUS8
EDPCWKNEITHDEHC	PHF21B	341	Q96EK2
VHEDCPLLSDQAWHV	PAPLN	476	O95428
QDPCSWVDKLSTVHH	TMEM144	171	Q7Z5S9
QHFLTCPSSTDEKAW	SNX18	376	Q96RF0
ISHWPNECIRHSASV	nan	81	Q8N8P6
ADKVVCTESWPLAHH	NPY4R2	196	P0DQD5
WVLTAAHCTKDASDP	TMPRSS12	116	Q86WS5
TDAHTLSGWAPVCVH	PKHD1L1	2146	Q86WI1
LATVTPWDSCHHEAA	SLAMF8	211	Q9P0V8
VWSNSEQDCLPHSFH	PTH2R	496	P49190
PSVCQRHEKTHWRET	ZNF563	461	Q8TA94
SESHSHWVHSPIECT	EDA2R	241	Q9HAV5
HWVHSPIECTELDLQ	EDA2R	246	Q9HAV5
CHQWLRPETHTKEQI	ZSCAN12	71	O43309
VLTMHHCADPNTEDW	UNC5C	606	O95185
SWQQDHCPPKLTEFH	MST1R	561	Q04912
EWKPHSNTKCEEASH	ZNF772	246	Q68DY9
IICPASLIHHWKNEV	TTF2	646	Q9UNY4
CWSTCTLSHDIHTPV	ZC3HAV1L	121	Q96H79
TAANSKWIQEHPECA	AGL	221	P35573
VSWAHSHGTICSLIP	KIAA1958	16	Q8N8K9
LHQWTCLPDQSDVIH	NEB	2871	P20929